VarmX Enrolls First Participant in Global Phase 3 EquilibriX-S Trial of VMX-C001 for Urgent Surgery
核心洞察
VarmX (搜索) has enrolled the first participant in its global Phase 3 EquilibriX-S trial (NCT07288489), a registrational study of VMX-C001 versus usual pharmacologic care in patients taking FXa inhibitors who require urgent surgery or procedures.
The randomized, controlled study will recruit participants across more than 20 countries to assess whether a single intravenous dose of VMX-C001 can rapidly restore hemostasis during urgent surgery.
VMX-C001 is a recombinant modified human coagulation Factor X protein engineered to be insensitive to Factor Xa inhibitors (搜索), designed for fixed-dose IV administration with a minimized thrombotic risk profile.
VarmX (搜索), a biotech company developing approaches to bypass direct oral anticoagulants targeting activated factor Xa (FXa inhibitors), has enrolled the first participant in its global Phase 3 EquilibriX-S trial. The landmark registrational study is evaluating the company's lead asset, VMX-C001, for the rapid restoration of normal coagulation in patients taking any FXa inhibitor who require an urgent surgery or procedure.
The announcement, made from Leiden, The Netherlands, marks the initiation of a randomized, controlled Phase 3 study that will enroll participants across more than 20 countries. The trial will examine whether a single intravenous dose of VMX-C001 can reliably and quickly restore hemostasis during urgent surgical procedures in participants receiving FXa inhibitors within the previous 15 hours.
Trial Design and Endpoints
EquilibriX-S (NCT07288489) compares VMX-C001 against usual pharmacologic care in patients taking FXa inhibitors who require urgent surgery or procedures. The primary endpoint is the proportion of participants achieving good or excellent hemostatic efficacy, with safety endpoints also being evaluated. The clinical efficacy and safety endpoints are designed to support worldwide regulatory submissions.
Mechanism and Therapeutic Rationale
VMX-C001 is a recombinant modified human coagulation Factor X protein engineered to be insensitive to Factor Xa inhibitors (搜索). The therapy is designed to bypass the anticoagulant activity of FXa inhibitors and support restoration of the coagulation cascade. Beyond coagulation restoration, VMX-C001's potential advantages include fixed-dose administration regardless of the specific FXa inhibitor used, rapid IV delivery, preservation of common anticoagulants such as heparin, and a minimized thrombotic risk profile.
These properties are being evaluated as part of the ongoing pivotal Phase 3 clinical trial EquilibriX-S, with the aim of establishing VMX-C001 as a treatment option for patients on FXa inhibitors requiring emergency surgery.
Unmet Need and Disease Burden
The clinical need addressed by VMX-C001 is substantial. By 2030, approximately 30 million patients in the U.S., Europe, and Japan are expected to receive FXa inhibitors as chronic anticoagulation therapy, including for stroke prevention in atrial fibrillation (搜索) and the prevention of deep vein thrombosis (搜索). Each week, more than 30,000 of these patients experience severe life-threatening bleeding or require emergency surgery, where the risk of bleeding poses a critical challenge.
Leadership Perspective
John Glasspool, Chief Executive Officer of VarmX (搜索), commented: "Enrolling the first participant in EquilibriX-S marks a significant milestone for VarmX and for the millions of patients taking Factor Xa inhibitors (搜索) who may one day need an urgent surgery or procedure. VMX-C001 has shown the potential to restore coagulation regardless of which FXa inhibitor a patient is taking, and this Phase 3 trial will provide the pivotal data needed for regulatory approval. We are grateful to our dedicated team, investigators, clinical partners and our strategic collaborator, CSL (搜索), for their efforts in bringing this programme to patients."
Company Background
VarmX (搜索) was spun out from Leiden University Medical Center (LUMC) in 2016 by Professor Pieter Reitsma, a leading expert in hemostasis and thrombosis. The company's lead compound, VMX-C001, is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (搜索) (FXa DOACs) as anticoagulation therapy. VarmX is supported by a syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences, Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter. Most recently, VarmX signed a strategic collaboration with CSL (搜索) to fund the EquilibriX-S trial.